Vimian Group AB (VIMIAN) - Total Liabilities

Latest as of December 2025: Skr401.00 Million SEK ≈ $43.15 Million USD

Based on the latest financial reports, Vimian Group AB (VIMIAN) has total liabilities worth Skr401.00 Million SEK (≈ $43.15 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital position of Vimian Group AB to evaluate short-term liquidity relative to the company's equity base.

Vimian Group AB - Total Liabilities Trend (2017–2025)

This chart illustrates how Vimian Group AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Vimian Group AB assets under control.

Vimian Group AB Competitors by Total Liabilities

The table below lists competitors of Vimian Group AB ranked by their total liabilities.

Company Country Total Liabilities
Tung Ho Steel Enterprise Corp
TW:2006
Taiwan NT$19.09 Billion
Ruentex Industries Ltd
TW:2915
Taiwan NT$14.94 Billion
Bet Shemesh Engines Holdings 1997 Ltd
TA:BSEN
Israel ILA165.98 Million
Uniti Group Inc.
LSE:0LJB
UK $12.82 Billion
Spartan Resources Ltd
AU:SPR
Australia AU$124.04 Million
Zhejiang Weixing Industrial Development Co Ltd
SHE:002003
China CN¥2.28 Billion
Intralot S.A. Integrated Lottery Systems and Services
AT:INLOT
Greece €1.35 Billion
Bomin Electronics Co Ltd
SHG:603936
China CN¥6.72 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Vimian Group AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See VIMIAN net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.57 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.36 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vimian Group AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vimian Group AB (2017–2025)

The table below shows the annual total liabilities of Vimian Group AB from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 Skr401.00 Million
≈ $43.15 Million
-0.57%
2024-12-31 Skr403.30 Million
≈ $43.40 Million
-9.77%
2023-12-31 Skr446.97 Million
≈ $48.10 Million
+1.11%
2022-12-31 Skr442.06 Million
≈ $47.57 Million
+56.72%
2021-12-31 Skr282.08 Million
≈ $30.36 Million
+54.95%
2020-12-31 Skr182.05 Million
≈ $19.59 Million
+286.72%
2019-12-31 Skr47.08 Million
≈ $5.07 Million
+244.90%
2018-12-31 Skr13.65 Million
≈ $1.47 Million
--
2017-12-31 Skr0.00
≈ $0.00
--

About Vimian Group AB

ST:VIMIAN Sweden Diagnostics & Research
Market Cap
$2.02 Billion
Skr18.72 Billion SEK
Market Cap Rank
#6149 Global
#90 in Sweden
Share Price
Skr35.60
Change (1 day)
+0.71%
52-Week Range
Skr24.92 - Skr35.85
All Time High
Skr117.16
About

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic… Read more